查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
充血性心臟衰竭 (CHF) 市場 - 成長、未來前景、競爭分析，2023-2031 年
市場調查報告書
商品編碼
1355788

充血性心臟衰竭 (CHF) 市場 - 成長、未來前景、競爭分析，2023-2031 年

Congestive Heart Failure (CHF) Market - Growth, Future Prospects and Competitive Analysis, 2023 - 2031
出版日期: | 出版商: Acute Market Reports | 英文 119 Pages | 商品交期: 最快1-2個工作天內

價格

充血性心臟衰竭 (CHF) 也稱為心臟衰竭，是一種慢性疾病，會降低心臟有效泵血的能力。 當心肌變弱或受損，導致含氧血液供應不足以滿足身體需求時，就會發生這種情況。 結果，液體積聚在身體的各個部位，導致呼吸短促、疲勞、腳和腳踝腫脹（水腫）以及身體活動困難等症狀。 預計 2023 年至 2031 年期間，充血性心臟衰竭治療藥物市場將以 14.5% 的複合年增長率成長。 心臟病的流行加上醫療技術的進步將維持對有效的慢性心臟衰竭治療的需求。 監管挑戰仍將持續，公司將需要應對複雜的審批流程。 按類別和銷售管道進行市場細分對於滿足不同的患者需求仍然很重要。

心臟病盛行率增加

CHF 治療市場的主要驅動力之一是全球心臟病盛行率的上升。 世界衛生組織（WHO）將心血管疾病列為全球第一大死因。 充血性心臟衰竭盛行率不斷上升，久坐的生活方式和不良飲食等因素加劇了這種情況，顯著增加了對有效治療方案的需求。 隨著人口老化，心臟病相關疾病的負擔預計將增加，進一步推動市場成長。

醫療技術的進步

由於醫療技術的進步，CHF的治療狀況已徹底改變。 藥物輸送系統、個人化醫療方法和新型化合物的開發的創新顯著改善了患者的治療效果。 特別是，沙庫巴曲/纈沙坦（Entrest）的推出代表了射血分數降低心臟衰竭治療的突破。 這些進步不僅提高了治療的有效性，而且還擴大了醫療保健專業人員和患者可用的治療選擇。

重視早期診斷、早期治療

促進心臟病的早期診斷和及時治療的努力正在對 CHF 治療市場產生積極影響。 醫療保健組織和政府努力提高人們對心臟健康的認識以及早期幹預的好處，從而提高了患者的認識。 心臟衰竭的早期發現使醫療保健專業人員能夠實施預防疾病進展和改善整體生活品質的治療策略。 這些努力的累積正在推動CHF治療藥物的需求。

嚴格的監理要求

CHF治療市場在不斷成長的同時，也面臨嚴格監管要求帶來的挑戰。 新藥的開發和獲得批准的過程複雜且耗時。 FDA 和 EMA 等監管機構對新藥候選物施加嚴格的安全性和有效性標準，從而延長了開發時間並增加了成本。 對於中小型製藥公司來說，適應監管環境尤其困難，並且限制了市場成長。

血管張力素 2 受體拮抗劑依類別主導市場

2022 年，血管張力素 2 受體阻斷劑 (ARB) 的銷售額創下最高紀錄。 血管緊張素 2 受體拮抗劑是透過阻斷血管緊張素 II 的作用的藥物，血管緊張素 II 是一種導致血管收縮和液體滯留的激素。 透過抑制這些作用，ARB 可以放鬆血管、降低血壓、減輕心臟負擔。 ARB 通常用於治療 CHF 和高血壓等相關疾病。 它常與ACE抑制劑、β受體阻斷劑、利尿劑等其他藥物合併使用，為心臟衰竭患者提供綜合治療。 這些藥物可以改善症狀，增加心臟的泵血能力，並有助於更好的整體疾病管理。 血管張力素 2 受體拮抗劑由於其既定療效和廣泛使用，歷來在 CHF 治療市場上產生了可觀的收入。 血管張力素 2 受體拮抗劑是許多患者治療方案的重要組成部分，因為它們可以解決心臟衰竭治療的多個方面。 然而，值得注意的是，每個藥物類別產生的收入可能會根據市場動態、定價、患者偏好和新治療方案的出現等因素而波動。

醫院藥局透過分銷管道主導市場

2022年，醫院藥局的銷售額最高。 醫院藥局是醫院內為住院病人和門診病人配藥的醫療機構。 這些藥房在為包括慢性心臟衰竭在內的急性疾病患者提供即時獲得基本藥物方面發揮著重要作用。 醫院藥局通常儲備多種藥物，包括心臟衰竭藥物，並由醫療專業人員監督，以確保患者接受正確的藥物和劑量。 對於患有嚴重心臟衰竭或其併發症的住院患者，可以直接靜脈注射或肌肉注射，醫院藥房也接待此類患者。

北美仍處於世界領先地位

CHF 治療市場的地理趨勢因地區而異。 由於醫療基礎設施發展的進步、老年人口的增加以及高血壓和糖尿病等危險因素的流行等綜合因素，複合年增長率最高的地區是亞太地區。 北美由於其完善的醫療保健系統、高額醫療支出以及對研發活動的重視，始終保持最高的銷售份額。

競爭趨勢與主要策略

在競爭激烈的 CHF 藥物市場中，領先公司正在採取各種策略來維持其市場地位並推動創新。 Bayer AG, Novartis AG, Merck &co., Inc., Astrazeneca, Bristol-Myers Squibb Company, Amgen Inc., BoehringerIngelheiminternationalGmbh, Pfizer, Inc., Johnson &Johnson Services, Inc., Otsuka Pharmaceutical Co., Ltd., Eli Lilly and Company, Novo Nordiska/S等著名公司，如諾和諾德公司(Novo Nordiska/S and Company) 一直在尋求合併、收購、合作夥伴關係和產品發布，以擴大其產品組合併加強其市場覆蓋範圍。 這些公司也大力投資研發，專注於精準治療、個人化醫療方法和改善病患治療效果。

目錄

第一章前言

  • 報告內容
    • 報告的目的
    • 目標受眾
    • 提供的主要產品
  • 市場區隔
  • 調查方法
    • 第一階段-二次調查
    • 第二階段 - 初步調查
    • 第三階段-專家評審
    • 先決條件
    • 採用的方法

第 2 章執行摘要

第 3 章充血性心臟衰竭 (CHF) 市場：競爭分析

  • 主要供應商的市場地位
  • 供應商採取的策略
  • 主要產業戰略
  • 層級分析：2022 年與 2031 年

第 4 章充血性心臟衰竭 (CHF) 市場：宏觀分析與市場動態

  • 簡介
  • 2021-2031 年世界充血性心臟衰竭 (CHF) 市場價值
  • 市場動態
    • 市場驅動因素
    • 市場限制因素
    • 主要挑戰
    • 主要機會
  • 促進因素和抑制因素的影響分析
  • 蹺蹺板分析

第 5 章充血性心臟衰竭 (CHF) 市場：依藥物類別 2021-2031

  • 市場概覽
  • 成長/利潤分析：2022 年與 2031 年
  • 市場區隔
    • ACE抑制劑
    • 血管張力素2受體阻斷劑
    • β受體阻斷劑
    • 利尿劑
    • 醛固酮拮抗劑
    • 正性肌力藥
    • 其他

第 6 章充血性心臟衰竭 (CHF) 市場：依通路劃分，2021-2031 年

  • 市場概覽
  • 成長/利潤分析：2022 年與 2031 年
  • 市場區隔
    • 醫院藥房
    • 零售藥局
    • 網路藥局

第 7 章北美充血性心臟衰竭 (CHF) 市場 2021-2031

  • 市場概覽
  • 充血性心臟衰竭 (CHF) 市場：依藥物類別劃分，2021-2031 年
  • 充血性心臟衰竭 (CHF) 市場：依通路劃分，2021-2031 年
  • 充血性心臟衰竭 (CHF) 市場：按地區劃分 2021-2031 年
    • 北美
      • 美國
      • 加拿大
      • 其他北美地區

第 8 章英國與歐盟充血性心臟衰竭 (CHF) 市場 2021-2031

  • 市場概覽
  • 充血性心臟衰竭 (CHF) 市場：依藥物類別劃分，2021-2031 年
  • 充血性心臟衰竭 (CHF) 市場：依通路劃分，2021-2031 年
  • 充血性心臟衰竭 (CHF) 市場：按地區劃分 2021-2031 年
    • 英國和歐盟
      • 英國
      • 德國
      • 西班牙
      • 義大利
      • 法國
      • 其他歐洲地區

第 9 章亞太地區充血性心臟衰竭 (CHF) 市場 2021-2031

  • 市場概覽
  • 充血性心臟衰竭 (CHF) 市場：依藥物類別劃分，2021-2031 年
  • 充血性心臟衰竭 (CHF) 市場：依通路劃分，2021-2031 年
  • 充血性心臟衰竭 (CHF) 市場：按地區劃分 2021-2031 年
    • 亞太地區
      • 中國
      • 日本
      • 印度
      • 澳大利亞
      • 韓國
      • 其他亞太地區

第 10 章 2021-2031 年拉丁美洲充血性心臟衰竭 (CHF) 市場

  • 市場概覽
  • 充血性心臟衰竭 (CHF) 市場：依藥物類別劃分，2021-2031 年
  • 充血性心臟衰竭 (CHF) 市場：依通路劃分，2021-2031 年
  • 充血性心臟衰竭 (CHF) 市場：按地區劃分 2021-2031 年
    • 拉丁美洲
      • 巴西
      • 墨西哥
      • 其他拉丁美洲地區

第 11 章中東與非洲充血性心臟衰竭 (CHF) 市場 2021-2031

  • 市場概覽
  • 充血性心臟衰竭 (CHF) 市場：依藥物類別劃分，2021-2031 年
  • 充血性心臟衰竭 (CHF) 市場：依通路劃分，2021-2031 年
  • 充血性心臟衰竭 (CHF) 市場：按地區劃分 2021-2031 年
    • 中東/非洲
      • 海灣合作委員會
      • 非洲
      • 其他中東/非洲地區

第十二章公司簡介

  • Bayer AGNovartis AG
  • Merck & co. Inc.
  • Astrazeneca
  • Bristol-Myers Squibb Company
  • Amgen Inc.
  • BoehringerIngelheiminternationalGmbh
  • Pfizer Inc.
  • Johnson & Johnson Services Inc.
  • Otsuka Pharmaceutical Co. Ltd.
  • Eli Lilly and Company
  • Novo Nordiska/S
  • 其他主要公司
Product Code: 139808-09-23

Congestive heart failure (CHF), also known as heart failure, is a chronic medical condition in which the heart's ability to pump blood efficiently is compromised. This condition occurs when the heart muscles become weakened or damaged, leading to an inadequate supply of oxygenated blood to meet the body's needs. As a result, fluid may accumulate in various parts of the body, causing symptoms such as shortness of breath, fatigue, swelling in the legs and ankles (edema), and difficulty performing physical activities. The congestive heart failure drug market is expected to grow at a CAGR of 14.5% during the forecast period of 2023 to 2031. The prevalence of heart diseases, coupled with ongoing advancements in medical technology, will sustain the demand for effective CHF treatments. Regulatory challenges will persist, requiring companies to navigate complex approval processes. Market segmentation by class and distribution channels will remain instrumental in catering to diverse patient needs.

Rising Prevalence of Heart Diseases

One of the primary drivers of the CHF drugs market is the escalating prevalence of heart diseases worldwide. The World Health Organization (WHO) has identified cardiovascular diseases as the leading cause of mortality globally. The growing incidence of congestive heart failure, exacerbated by factors like sedentary lifestyles and poor dietary habits, has substantially increased the demand for effective treatment options. As the population ages, the burden of heart-related ailments is projected to rise, further fueling the market's growth.

Advancements in Medical Technology

The landscape of CHF treatment has been revolutionized by advancements in medical technology. Innovations in drug delivery systems, personalized medicine approaches, and the development of novel drug compounds have significantly improved patient outcomes. Notably, the introduction of sacubitril/valsartan (Entresto) has marked a breakthrough in managing heart failure with reduced ejection fraction. Such advancements have not only enhanced the efficacy of treatments but have also expanded the treatment options available to healthcare providers and patients.

Focus on Early Diagnosis and Treatment

Efforts to promote early diagnosis and timely treatment of heart conditions have had a positive impact on the CHF drugs market. Initiatives by healthcare organizations and governments to raise awareness about heart health and the benefits of early intervention have led to increased patient awareness. By identifying heart failure in its early stages, medical professionals can implement treatment strategies that prevent disease progression and improve overall quality of life. These efforts have collectively driven the demand for CHF drugs.

Stringent Regulatory Requirements

While the CHF drugs market has experienced growth, it has also encountered challenges posed by stringent regulatory requirements. The process of developing and gaining approval for new drugs is complex and time-consuming. Regulatory agencies such as the FDA and EMA impose rigorous safety and efficacy standards on new drug candidates, leading to prolonged development timelines and elevated costs. Navigating the regulatory landscape can be particularly challenging for smaller pharmaceutical companies, acting as a restraint on market growth.

Angiotensin 2 Receptor Blockers Dominated Market by Class

In 2022, Angiotensin 2 Receptor Blockers (ARBs) held highest revenue. Angiotensin 2 Receptor Blockers are a class of medications that work by blocking the effects of the hormone angiotensin II, which can lead to blood vessel constriction and fluid retention. By blocking these effects, ARBs help relax blood vessels, reduce blood pressure, and decrease the workload on the heart. ARBs are commonly prescribed to manage CHF and related conditions, such as hypertension. They are often used in combination with other medications, such as ACE inhibitors, beta blockers, and diuretics, to provide comprehensive treatment for heart failure patients. These medications can help improve symptoms, enhance the heart's pumping efficiency, and overall contribute to better management of the condition. Due to their established efficacy and widespread use, Angiotensin 2 Receptor Blockers have historically generated substantial revenue in the CHF drugs market. Their ability to address multiple aspects of heart failure management makes them a critical component of treatment regimens for many patients. However, it's important to note that the revenue generated by each drug class can vary based on factors such as market dynamics, pricing, patient preferences, and the emergence of newer treatment options.

Hospital Pharmacies Dominates Market by Distribution Channel

In 2022, Hospital Pharmacies held highest revenue. Hospital Pharmacies are healthcare facilities within hospitals that dispense medications to both inpatients and outpatients. These pharmacies play a crucial role in providing immediate access to essential medications for patients with acute conditions, including CHF. Hospital Pharmacies often have a wide range of medications available, including those for treating heart failure, and they ensure that patients receive the right medications and dosages under the supervision of healthcare professionals. Patients hospitalized due to severe CHF or related complications may have their medications administered directly through intravenous (IV) or intramuscular (IM) injections, which are facilitated by Hospital Pharmacies.

North America Remains as the Global Leader

The geographic trends in the CHF drugs market reveal varying patterns across regions. The region with the highest CAGR is Asia-Pacific, driven by a combination of factors such as increasing healthcare infrastructure development, a rising geriatric population, and the prevalence of risk factors like hypertension and diabetes. North America has consistently held the highest revenue share, attributed to its well-established healthcare systems, significant healthcare expenditure, and a robust focus on research and development activities.

Competitive Trends and Key Strategies

In the fiercely Competitive Landscape of the CHF drugs market, leading players have adopted diverse strategies to maintain their market presence and drive innovation. Notable players like Bayer AG,Novartis AG, Merck & co., Inc., Astrazeneca, Bristol-Myers Squibb Company, Amgen Inc., BoehringerIngelheiminternationalGmbh, Pfizer, Inc., Johnson & Johnson Services, Inc., Otsuka Pharmaceutical Co., Ltd., Eli Lilly and Company, and Novo Nordiska/S have pursued mergers, acquisitions, collaborations, and product launches to expand their portfolios and enhance their market reach. These companies are also investing heavily in research and development endeavors, focusing on precision therapies, personalized medicine approaches, and improved patient outcomes.

Historical & Forecast Period

This study report represents analysis of each segment from 2021 to 2031 considering 2022 as the base year. Compounded Annual Growth Rate (CAGR) for each of the respective segments estimated for the forecast period of 2023 to 2031.

The current report comprises of quantitative market estimations for each micro market for every geographical region and qualitative market analysis such as micro and macro environment analysis, market trends, competitive intelligence, segment analysis, porters five force model, top winning strategies, top investment markets, emerging trends and technological analysis, case studies, strategic conclusions and recommendations and other key market insights.

Research Methodology

The complete research study was conducted in three phases, namely: secondary research, primary research, and expert panel review. key data point that enables the estimation ofCongestive Heart Failure (CHF) market are as follows:

  • Research and development budgets of manufacturers and government spending
  • Revenues of key companies in the market segment
  • Number of end users and consumption volume, price and value.

Geographical revenues generate by countries considered in the report:

Micro and macro environment factors that are currently influencing the Congestive Heart Failure (CHF) market and their expected impact during the forecast period.

Market forecast was performed through proprietary software that analyzes various qualitative and quantitative factors. Growth rate and CAGR were estimated through intensive secondary and primary research. Data triangulation across various data points provides accuracy across various analyzed market segments in the report. Application of both top down and bottom-up approach for validation of market estimation assures logical, methodical and mathematical consistency of the quantitative data.

Market Segmentation

Drug Class

  • ACE Inhibitors
  • Angiotensin 2 Receptor Blockers
  • Beta Blockers
  • Diuretics
  • Aldosterone Antagonists
  • Inotropes
  • Others

Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

Region Segment (2021-2031; US$ Million)

  • North America
    • U.S.
    • Canada
    • Rest of North America
  • UK and European Union
    • UK
    • Germany
    • Spain
    • Italy
    • France
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • Australia
    • South Korea
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East and Africa
    • GCC
    • Africa
    • Rest of Middle East and Africa

Key questions answered in this report:

  • What are the key micro and macro environmental factors that are impacting the growth of Congestive Heart Failure (CHF) market?
  • What are the key investment pockets with respect to product segments and geographies currently and during the forecast period?
  • Estimated forecast and market projections up to 2031.
  • Which segment accounts for the fastest CAGR during the forecast period?
  • Which market segment holds a larger market share and why?
  • Are low and middle-income economies investing in the Congestive Heart Failure (CHF) market?
  • Which is the largest regional market for Congestive Heart Failure (CHF) market?
  • What are the market trends and dynamics in emerging markets such as Asia Pacific, Latin America, and Middle East & Africa?
  • Which are the key trends driving Congestive Heart Failure (CHF) market growth?
  • Who are the key competitors and what are their key strategies to enhance their market presence in the Congestive Heart Failure (CHF) market worldwide?

Table of Contents

1. Preface

  • 1.1. Report Description
    • 1.1.1. Purpose of the Report
    • 1.1.2. Target Audience
    • 1.1.3. Key Offerings
  • 1.2. Market Segmentation
  • 1.3. Research Methodology
    • 1.3.1. Phase I - Secondary Research
    • 1.3.2. Phase II - Primary Research
    • 1.3.3. Phase III - Expert Panel Review
    • 1.3.4. Assumptions
    • 1.3.5. Approach Adopted

2. Executive Summary

  • 2.1. Market Snapshot: Global Congestive Heart Failure (CHF) Market
  • 2.2. Global Congestive Heart Failure (CHF) Market, By Drug Class, 2022 (US$ Million)
  • 2.3. Global Congestive Heart Failure (CHF) Market, By Distribution Channel, 2022 (US$ Million)
  • 2.4. Global Congestive Heart Failure (CHF) Market, By Geography, 2022 (US$ Million)
  • 2.5. Attractive Investment Proposition by Geography, 2022

3. Congestive Heart Failure (CHF) Market: Competitive Analysis

  • 3.1. Market Positioning of Key Congestive Heart Failure (CHF) Market Vendors
  • 3.2. Strategies Adopted by Congestive Heart Failure (CHF) Market Vendors
  • 3.3. Key Industry Strategies
  • 3.4. Tier Analysis 2022 Versus 2031

4. Congestive Heart Failure (CHF) Market: Macro Analysis & Market Dynamics

  • 4.1. Introduction
  • 4.2. Global Congestive Heart Failure (CHF) Market Value, 2021 - 2031, (US$ Million)
  • 4.3. Market Dynamics
    • 4.3.1. Market Drivers
    • 4.3.2. Market Restraints
    • 4.3.3. Key Challenges
    • 4.3.4. Key Opportunities
  • 4.4. Impact Analysis of Drivers and Restraints
  • 4.5. See-Saw Analysis

5. Congestive Heart Failure (CHF) Market: By Drug Class, 2021-2031, USD (Million)

  • 5.1. Market Overview
  • 5.2. Growth & Revenue Analysis: 2022 Versus 2031
  • 5.3. Market Segmentation
    • 5.3.1. ACE Inhibitors
    • 5.3.2. Angiotensin 2 Receptor Blockers
    • 5.3.3. Beta Blockers
    • 5.3.4. Diuretics
    • 5.3.5. Aldosterone Antagonists
    • 5.3.6. Inotropes
    • 5.3.7. Others

6. Congestive Heart Failure (CHF) Market: By Distribution Channel, 2021-2031, USD (Million)

  • 6.1. Market Overview
  • 6.2. Growth & Revenue Analysis: 2022 Versus 2031
  • 6.3. Market Segmentation
    • 6.3.1. Hospital Pharmacies
    • 6.3.2. Retail Pharmacies
    • 6.3.3. Online Pharmacies

7. North America Congestive Heart Failure (CHF) Market, 2021-2031, USD (Million)

  • 7.1. Market Overview
  • 7.2. Congestive Heart Failure (CHF) Market: By Drug Class, 2021-2031, USD (Million)
  • 7.3. Congestive Heart Failure (CHF) Market: By Distribution Channel, 2021-2031, USD (Million)
  • 7.4.Congestive Heart Failure (CHF) Market: By Region, 2021-2031, USD (Million)
    • 7.4.1.North America
      • 7.4.1.1. U.S.
        • 7.4.1.1.1. Congestive Heart Failure (CHF) Market: By Drug Class, 2021-2031, USD (Million)
        • 7.4.1.1.2. Congestive Heart Failure (CHF) Market: By Distribution Channel, 2021-2031, USD (Million)
      • 7.4.1.2. Canada
        • 7.4.1.2.1. Congestive Heart Failure (CHF) Market: By Drug Class, 2021-2031, USD (Million)
        • 7.4.1.2.2. Congestive Heart Failure (CHF) Market: By Distribution Channel, 2021-2031, USD (Million)
      • 7.4.1.3. Rest of North America
        • 7.4.1.3.1. Congestive Heart Failure (CHF) Market: By Drug Class, 2021-2031, USD (Million)
        • 7.4.1.3.2. Congestive Heart Failure (CHF) Market: By Distribution Channel, 2021-2031, USD (Million)

8. UK and European Union Congestive Heart Failure (CHF) Market, 2021-2031, USD (Million)

  • 8.1. Market Overview
  • 8.2. Congestive Heart Failure (CHF) Market: By Drug Class, 2021-2031, USD (Million)
  • 8.3. Congestive Heart Failure (CHF) Market: By Distribution Channel, 2021-2031, USD (Million)
  • 8.4.Congestive Heart Failure (CHF) Market: By Region, 2021-2031, USD (Million)
    • 8.4.1.UK and European Union
      • 8.4.1.1. UK
        • 8.4.1.1.1. Congestive Heart Failure (CHF) Market: By Drug Class, 2021-2031, USD (Million)
        • 8.4.1.1.2. Congestive Heart Failure (CHF) Market: By Distribution Channel, 2021-2031, USD (Million)
      • 8.4.1.2. Germany
        • 8.4.1.2.1. Congestive Heart Failure (CHF) Market: By Drug Class, 2021-2031, USD (Million)
        • 8.4.1.2.2. Congestive Heart Failure (CHF) Market: By Distribution Channel, 2021-2031, USD (Million)
      • 8.4.1.3. Spain
        • 8.4.1.3.1. Congestive Heart Failure (CHF) Market: By Drug Class, 2021-2031, USD (Million)
        • 8.4.1.3.2. Congestive Heart Failure (CHF) Market: By Distribution Channel, 2021-2031, USD (Million)
      • 8.4.1.4. Italy
        • 8.4.1.4.1. Congestive Heart Failure (CHF) Market: By Drug Class, 2021-2031, USD (Million)
        • 8.4.1.4.2. Congestive Heart Failure (CHF) Market: By Distribution Channel, 2021-2031, USD (Million)
      • 8.4.1.5. France
        • 8.4.1.5.1. Congestive Heart Failure (CHF) Market: By Drug Class, 2021-2031, USD (Million)
        • 8.4.1.5.2. Congestive Heart Failure (CHF) Market: By Distribution Channel, 2021-2031, USD (Million)
      • 8.4.1.6. Rest of Europe
        • 8.4.1.6.1. Congestive Heart Failure (CHF) Market: By Drug Class, 2021-2031, USD (Million)
        • 8.4.1.6.2. Congestive Heart Failure (CHF) Market: By Distribution Channel, 2021-2031, USD (Million)

9. Asia Pacific Congestive Heart Failure (CHF) Market, 2021-2031, USD (Million)

  • 9.1. Market Overview
  • 9.2. Congestive Heart Failure (CHF) Market: By Drug Class, 2021-2031, USD (Million)
  • 9.3. Congestive Heart Failure (CHF) Market: By Distribution Channel, 2021-2031, USD (Million)
  • 9.4.Congestive Heart Failure (CHF) Market: By Region, 2021-2031, USD (Million)
    • 9.4.1.Asia Pacific
      • 9.4.1.1. China
        • 9.4.1.1.1. Congestive Heart Failure (CHF) Market: By Drug Class, 2021-2031, USD (Million)
        • 9.4.1.1.2. Congestive Heart Failure (CHF) Market: By Distribution Channel, 2021-2031, USD (Million)
      • 9.4.1.2. Japan
        • 9.4.1.2.1. Congestive Heart Failure (CHF) Market: By Drug Class, 2021-2031, USD (Million)
        • 9.4.1.2.2. Congestive Heart Failure (CHF) Market: By Distribution Channel, 2021-2031, USD (Million)
      • 9.4.1.3. India
        • 9.4.1.3.1. Congestive Heart Failure (CHF) Market: By Drug Class, 2021-2031, USD (Million)
        • 9.4.1.3.2. Congestive Heart Failure (CHF) Market: By Distribution Channel, 2021-2031, USD (Million)
      • 9.4.1.4. Australia
        • 9.4.1.4.1. Congestive Heart Failure (CHF) Market: By Drug Class, 2021-2031, USD (Million)
        • 9.4.1.4.2. Congestive Heart Failure (CHF) Market: By Distribution Channel, 2021-2031, USD (Million)
      • 9.4.1.5. South Korea
        • 9.4.1.5.1. Congestive Heart Failure (CHF) Market: By Drug Class, 2021-2031, USD (Million)
        • 9.4.1.5.2. Congestive Heart Failure (CHF) Market: By Distribution Channel, 2021-2031, USD (Million)
      • 9.4.1.6. Rest of Asia Pacific
        • 9.4.1.6.1. Congestive Heart Failure (CHF) Market: By Drug Class, 2021-2031, USD (Million)
        • 9.4.1.6.2. Congestive Heart Failure (CHF) Market: By Distribution Channel, 2021-2031, USD (Million)

10. Latin America Congestive Heart Failure (CHF) Market, 2021-2031, USD (Million)

  • 10.1. Market Overview
  • 10.2. Congestive Heart Failure (CHF) Market: By Drug Class, 2021-2031, USD (Million)
  • 10.3. Congestive Heart Failure (CHF) Market: By Distribution Channel, 2021-2031, USD (Million)
  • 10.4.Congestive Heart Failure (CHF) Market: By Region, 2021-2031, USD (Million)
    • 10.4.1.Latin America
      • 10.4.1.1. Brazil
        • 10.4.1.1.1. Congestive Heart Failure (CHF) Market: By Drug Class, 2021-2031, USD (Million)
        • 10.4.1.1.2. Congestive Heart Failure (CHF) Market: By Distribution Channel, 2021-2031, USD (Million)
      • 10.4.1.2. Mexico
        • 10.4.1.2.1. Congestive Heart Failure (CHF) Market: By Drug Class, 2021-2031, USD (Million)
        • 10.4.1.2.2. Congestive Heart Failure (CHF) Market: By Distribution Channel, 2021-2031, USD (Million)
      • 10.4.1.3. Rest of Latin America
        • 10.4.1.3.1. Congestive Heart Failure (CHF) Market: By Drug Class, 2021-2031, USD (Million)
        • 10.4.1.3.2. Congestive Heart Failure (CHF) Market: By Distribution Channel, 2021-2031, USD (Million)

11. Middle East and Africa Congestive Heart Failure (CHF) Market, 2021-2031, USD (Million)

  • 11.1. Market Overview
  • 11.2. Congestive Heart Failure (CHF) Market: By Drug Class, 2021-2031, USD (Million)
  • 11.3. Congestive Heart Failure (CHF) Market: By Distribution Channel, 2021-2031, USD (Million)
  • 11.4.Congestive Heart Failure (CHF) Market: By Region, 2021-2031, USD (Million)
    • 11.4.1.Middle East and Africa
      • 11.4.1.1. GCC
        • 11.4.1.1.1. Congestive Heart Failure (CHF) Market: By Drug Class, 2021-2031, USD (Million)
        • 11.4.1.1.2. Congestive Heart Failure (CHF) Market: By Distribution Channel, 2021-2031, USD (Million)
      • 11.4.1.2. Africa
        • 11.4.1.2.1. Congestive Heart Failure (CHF) Market: By Drug Class, 2021-2031, USD (Million)
        • 11.4.1.2.2. Congestive Heart Failure (CHF) Market: By Distribution Channel, 2021-2031, USD (Million)
      • 11.4.1.3. Rest of Middle East and Africa
        • 11.4.1.3.1. Congestive Heart Failure (CHF) Market: By Drug Class, 2021-2031, USD (Million)
        • 11.4.1.3.2. Congestive Heart Failure (CHF) Market: By Distribution Channel, 2021-2031, USD (Million)

12. Company Profile

  • 12.1. Bayer AG,Novartis AG
    • 12.1.1. Company Overview
    • 12.1.2. Financial Performance
    • 12.1.3. Product Portfolio
    • 12.1.4. Strategic Initiatives
  • 12.2. Merck & co., Inc.
    • 12.2.1. Company Overview
    • 12.2.2. Financial Performance
    • 12.2.3. Product Portfolio
    • 12.2.4. Strategic Initiatives
  • 12.3. Astrazeneca
    • 12.3.1. Company Overview
    • 12.3.2. Financial Performance
    • 12.3.3. Product Portfolio
    • 12.3.4. Strategic Initiatives
  • 12.4. Bristol-Myers Squibb Company
    • 12.4.1. Company Overview
    • 12.4.2. Financial Performance
    • 12.4.3. Product Portfolio
    • 12.4.4. Strategic Initiatives
  • 12.5. Amgen Inc.
    • 12.5.1. Company Overview
    • 12.5.2. Financial Performance
    • 12.5.3. Product Portfolio
    • 12.5.4. Strategic Initiatives
  • 12.6. BoehringerIngelheiminternationalGmbh
    • 12.6.1. Company Overview
    • 12.6.2. Financial Performance
    • 12.6.3. Product Portfolio
    • 12.6.4. Strategic Initiatives
  • 12.7. Pfizer, Inc.
    • 12.7.1. Company Overview
    • 12.7.2. Financial Performance
    • 12.7.3. Product Portfolio
    • 12.7.4. Strategic Initiatives
  • 12.8. Johnson & Johnson Services, Inc.
    • 12.8.1. Company Overview
    • 12.8.2. Financial Performance
    • 12.8.3. Product Portfolio
    • 12.8.4. Strategic Initiatives
  • 12.9. Otsuka Pharmaceutical Co., Ltd.
    • 12.9.1. Company Overview
    • 12.9.2. Financial Performance
    • 12.9.3. Product Portfolio
    • 12.9.4. Strategic Initiatives
  • 12.10. Eli Lilly and Company
    • 12.10.1. Company Overview
    • 12.10.2. Financial Performance
    • 12.10.3. Product Portfolio
    • 12.10.4. Strategic Initiatives
  • 12.11. Novo Nordiska/S
    • 12.11.1. Company Overview
    • 12.11.2. Financial Performance
    • 12.11.3. Product Portfolio
    • 12.11.4. Strategic Initiatives
  • 12.12. Other Notable Players
    • 12.12.1. Company Overview
    • 12.12.2. Financial Performance
    • 12.12.3. Product Portfolio
    • 12.12.4. Strategic Initiatives

List of Tables

  • TABLE 1 Global Congestive Heart Failure (CHF) Market By Drug Class, 2021-2031, USD (Million)
  • TABLE 2 Global Congestive Heart Failure (CHF) Market By Distribution Channel, 2021-2031, USD (Million)
  • TABLE 3 North America Congestive Heart Failure (CHF) Market By Drug Class, 2021-2031, USD (Million)
  • TABLE 4 North America Congestive Heart Failure (CHF) Market By Distribution Channel, 2021-2031, USD (Million)
  • TABLE 5 U.S. Congestive Heart Failure (CHF) Market By Drug Class, 2021-2031, USD (Million)
  • TABLE 6 U.S. Congestive Heart Failure (CHF) Market By Distribution Channel, 2021-2031, USD (Million)
  • TABLE 7 Canada Congestive Heart Failure (CHF) Market By Drug Class, 2021-2031, USD (Million)
  • TABLE 8 Canada Congestive Heart Failure (CHF) Market By Distribution Channel, 2021-2031, USD (Million)
  • TABLE 9 Rest of North America Congestive Heart Failure (CHF) Market By Drug Class, 2021-2031, USD (Million)
  • TABLE 10 Rest of North America Congestive Heart Failure (CHF) Market By Distribution Channel, 2021-2031, USD (Million)
  • TABLE 11 UK and European Union Congestive Heart Failure (CHF) Market By Drug Class, 2021-2031, USD (Million)
  • TABLE 12 UK and European Union Congestive Heart Failure (CHF) Market By Distribution Channel, 2021-2031, USD (Million)
  • TABLE 13 UK Congestive Heart Failure (CHF) Market By Drug Class, 2021-2031, USD (Million)
  • TABLE 14 UK Congestive Heart Failure (CHF) Market By Distribution Channel, 2021-2031, USD (Million)
  • TABLE 15 Germany Congestive Heart Failure (CHF) Market By Drug Class, 2021-2031, USD (Million)
  • TABLE 16 Germany Congestive Heart Failure (CHF) Market By Distribution Channel, 2021-2031, USD (Million)
  • TABLE 17 Spain Congestive Heart Failure (CHF) Market By Drug Class, 2021-2031, USD (Million)
  • TABLE 18 Spain Congestive Heart Failure (CHF) Market By Distribution Channel, 2021-2031, USD (Million)
  • TABLE 19 Italy Congestive Heart Failure (CHF) Market By Drug Class, 2021-2031, USD (Million)
  • TABLE 20 Italy Congestive Heart Failure (CHF) Market By Distribution Channel, 2021-2031, USD (Million)
  • TABLE 21 France Congestive Heart Failure (CHF) Market By Drug Class, 2021-2031, USD (Million)
  • TABLE 22 France Congestive Heart Failure (CHF) Market By Distribution Channel, 2021-2031, USD (Million)
  • TABLE 23 Rest of Europe Congestive Heart Failure (CHF) Market By Drug Class, 2021-2031, USD (Million)
  • TABLE 24 Rest of Europe Congestive Heart Failure (CHF) Market By Distribution Channel, 2021-2031, USD (Million)
  • TABLE 25 Asia Congestive Heart Failure (CHF) Market By Drug Class, 2021-2031, USD (Million)
  • TABLE 26 Asia Congestive Heart Failure (CHF) Market By Distribution Channel, 2021-2031, USD (Million)
  • TABLE 27 China Congestive Heart Failure (CHF) Market By Drug Class, 2021-2031, USD (Million)
  • TABLE 28 China Congestive Heart Failure (CHF) Market By Distribution Channel, 2021-2031, USD (Million)
  • TABLE 29 Japan Congestive Heart Failure (CHF) Market By Drug Class, 2021-2031, USD (Million)
  • TABLE 30 Japan Congestive Heart Failure (CHF) Market By Distribution Channel, 2021-2031, USD (Million)
  • TABLE 31 India Congestive Heart Failure (CHF) Market By Drug Class, 2021-2031, USD (Million)
  • TABLE 32 India Congestive Heart Failure (CHF) Market By Distribution Channel, 2021-2031, USD (Million)
  • TABLE 33 Australia Congestive Heart Failure (CHF) Market By Drug Class, 2021-2031, USD (Million)
  • TABLE 34 Australia Congestive Heart Failure (CHF) Market By Distribution Channel, 2021-2031, USD (Million)
  • TABLE 35 South Korea Congestive Heart Failure (CHF) Market By Drug Class, 2021-2031, USD (Million)
  • TABLE 36 South Korea Congestive Heart Failure (CHF) Market By Distribution Channel, 2021-2031, USD (Million)
  • TABLE 37 Latin America Congestive Heart Failure (CHF) Market By Drug Class, 2021-2031, USD (Million)
  • TABLE 38 Latin America Congestive Heart Failure (CHF) Market By Distribution Channel, 2021-2031, USD (Million)
  • TABLE 39 Brazil Congestive Heart Failure (CHF) Market By Drug Class, 2021-2031, USD (Million)
  • TABLE 40 Brazil Congestive Heart Failure (CHF) Market By Distribution Channel, 2021-2031, USD (Million)
  • TABLE 41 Mexico Congestive Heart Failure (CHF) Market By Drug Class, 2021-2031, USD (Million)
  • TABLE 42 Mexico Congestive Heart Failure (CHF) Market By Distribution Channel, 2021-2031, USD (Million)
  • TABLE 43 Rest of Latin America Congestive Heart Failure (CHF) Market By Drug Class, 2021-2031, USD (Million)
  • TABLE 44 Rest of Latin America Congestive Heart Failure (CHF) Market By Distribution Channel, 2021-2031, USD (Million)
  • TABLE 45 Middle East and Africa Congestive Heart Failure (CHF) Market By Drug Class, 2021-2031, USD (Million)
  • TABLE 46 Middle East and Africa Congestive Heart Failure (CHF) Market By Distribution Channel, 2021-2031, USD (Million)
  • TABLE 47 GCC Congestive Heart Failure (CHF) Market By Drug Class, 2021-2031, USD (Million)
  • TABLE 48 GCC Congestive Heart Failure (CHF) Market By Distribution Channel, 2021-2031, USD (Million)
  • TABLE 49 Africa Congestive Heart Failure (CHF) Market By Drug Class, 2021-2031, USD (Million)
  • TABLE 50 Africa Congestive Heart Failure (CHF) Market By Distribution Channel, 2021-2031, USD (Million)
  • TABLE 51 Rest of Middle East and Africa Congestive Heart Failure (CHF) Market By Drug Class, 2021-2031, USD (Million)
  • TABLE 52 Rest of Middle East and Africa Congestive Heart Failure (CHF) Market By Distribution Channel, 2021-2031, USD (Million)

List of Figures

  • FIG. 1 Global Congestive Heart Failure (CHF) Market: Market Coverage
  • FIG. 2 Research Methodology and Data Sources
  • FIG. 3 Market Size Estimation - Top Down & Bottom-Up Approach
  • FIG. 4 Global Congestive Heart Failure (CHF) Market: Quality Assurance
  • FIG. 5 Global Congestive Heart Failure (CHF) Market, By Drug Class, 2022
  • FIG. 6 Global Congestive Heart Failure (CHF) Market, By Distribution Channel, 2022
  • FIG. 7 Global Congestive Heart Failure (CHF) Market, By Geography, 2022
  • FIG. 8 Market Geographical Opportunity Matrix - Global Congestive Heart Failure (CHF) Market, 2022

FIG. 9Market Positioning of Key Congestive Heart Failure (CHF) Market Players, 2022

FIG. 10Global Congestive Heart Failure (CHF) Market - Tier Analysis - Percentage of Revenues by Tier Level, 2022 Versus 2031

  • FIG. 11 Global Congestive Heart Failure (CHF) Market, By Drug Class, 2022 Vs 2031, %
  • FIG. 12 Global Congestive Heart Failure (CHF) Market, By Distribution Channel, 2022 Vs 2031, %
  • FIG. 13 U.S. Congestive Heart Failure (CHF) Market (US$ Million), 2021 - 2031
  • FIG. 14 Canada Congestive Heart Failure (CHF) Market (US$ Million), 2021 - 2031
  • FIG. 15 Rest of North America Congestive Heart Failure (CHF) Market (US$ Million), 2021 - 2031
  • FIG. 16 UK Congestive Heart Failure (CHF) Market (US$ Million), 2021 - 2031
  • FIG. 17 Germany Congestive Heart Failure (CHF) Market (US$ Million), 2021 - 2031
  • FIG. 18 Spain Congestive Heart Failure (CHF) Market (US$ Million), 2021 - 2031
  • FIG. 19 Italy Congestive Heart Failure (CHF) Market (US$ Million), 2021 - 2031
  • FIG. 20 France Congestive Heart Failure (CHF) Market (US$ Million), 2021 - 2031
  • FIG. 21 Rest of Europe Congestive Heart Failure (CHF) Market (US$ Million), 2021 - 2031
  • FIG. 22 China Congestive Heart Failure (CHF) Market (US$ Million), 2021 - 2031
  • FIG. 23 Japan Congestive Heart Failure (CHF) Market (US$ Million), 2021 - 2031
  • FIG. 24 India Congestive Heart Failure (CHF) Market (US$ Million), 2021 - 2031
  • FIG. 25 Australia Congestive Heart Failure (CHF) Market (US$ Million), 2021 - 2031
  • FIG. 26 South Korea Congestive Heart Failure (CHF) Market (US$ Million), 2021 - 2031
  • FIG. 27 Rest of Asia Congestive Heart Failure (CHF) Market (US$ Million), 2021 - 2031
  • FIG. 28 Brazil Congestive Heart Failure (CHF) Market (US$ Million), 2021 - 2031
  • FIG. 29 Mexico Congestive Heart Failure (CHF) Market (US$ Million), 2021 - 2031
  • FIG. 30 Rest of Latin America Congestive Heart Failure (CHF) Market (US$ Million), 2021 - 2031
  • FIG. 31 GCC Congestive Heart Failure (CHF) Market (US$ Million), 2021 - 2031
  • FIG. 32 Africa Congestive Heart Failure (CHF) Market (US$ Million), 2021 - 2031
  • FIG. 33 Rest of Middle East and Africa Congestive Heart Failure (CHF) Market (US$ Million), 2021 - 2031